Artikler

Sampo Group continued its solid financial performance in January-September 2025, driven by positive momentum across private and SME lines, and strong underwriting performance in a favourable claims environment.

Investors can determine how expensive or cheap a stock is relative to competitors or other available investments by using standardized metrics that enable apples-to-apples comparisons. These metrics are widely used by equity analysts and investors for investment screening and peer benchmarking, providing a starting point for identifying differences in pricing that later could be evaluated by the investor/analyst to determine whether a company is undervalued or overvalued. By standardizing a company's market value against its earnings, sales, assets, or cash flows, these ratios make it easier to compare businesses of different sizes and across industries.

Sampo reports its financial performance under four segments based on its operational business areas: Private Nordic, Private UK, Nordic Commercial and Nordic Industrial. In this blog series, we will introduce all our segments. First up is Private Nordic.

Inderes' Playbook gives the reader a deep dive into Inderes' business model, culture, leadership, organization model and future vision. The newly released edition is the fourth since the original Playbook was first published in 2019.

Despite the stock market volatility of recent weeks, private investors' risk appetite does not seem to have wavered in the United States, and the dip is being bought by the truckload. Has the risk appetite of young investors changed permanently?

U.S. President Donald Trump is pressuring Federal Reserve Chairman Jay Powell to cut interest rates, even though the Fed is, by law, an independent entity free from political influence. Next year, Trump will get to appoint a new Fed chair when Powell's term ends. A central bank under the president’s thumb would not restore the market’s waning confidence in U.S. politics. One might ask: Is the U.S. “on the road to Zimbabwe”?

The return of an investment portfolio relative to an index is a simple but brutally honest measure of stock picking success. A similar measure, we believe, will also serve as a tool for assessing the quality and independence of equity research.

Do you know how to code and are you interested in investing or information democratizing? Join our team to develop the platform, which is used by over 70,000 active investors.

Sampo Group sustained strong top-line growth and delivered robust underwriting profit growth in 2024, supported by solid development in all business areas.

Sampo’s Board has today resolved upon a share split based on the authorisation granted by the Annual General Meeting held on 25 April 2024.

Double materiality assessment is a tricky term, but in practice it is the point in sustainability reporting where the most relevant issues for the stock picker should be identified.

CSRD reports, or sustainability reports, will be part of mandatory annual reporting in the future. The reporting as a whole is very complex, and the aim of this new series of articles is to explain the key aspects of CSRD reporting for stock pickers.

The fourth part of our series of articles focusing on investing in Life Science companies deals with value creation in drug development companies through M&As and licensing agreements.

Sampo Group’s top line growth remained strong and underlying trends positive in January-September 2024, driving underwriting profit growth in a mixed claims environment.   

The second part of our series of articles focusing on the basics of investing in Life Science companies deals with the likelihood of successful drug development.

Buy low and sell high is the most overused phrase in the investment world. Theoretically, a strategy based on this phrase is probably one of the best investment strategies in hindsight, but often the cheap or expensive nature of a stock or investment can only be determined after the fact.

We are starting a series of articles focusing on the basics of investing in Life Science companies. This first part of the series describes the clinical phases of drug development that most drug development companies have to go through before they can apply for marketing authorization and commercialize a drug.